Literature DB >> 20178419

Estimating the cost of health care-associated infections: mind your p's and q's.

Nicholas Graves1, Stephan Harbarth, Jan Beyersmann, Adrian Barnett, Kate Halton, Ben Cooper.   

Abstract

Monetary valuations of the economic cost of health care-associated infections (HAIs) are important for decision making and should be estimated accurately. Erroneously high estimates of costs, designed to jolt decision makers into action, may do more harm than good in the struggle to attract funding for infection control. Expectations among policy makers might be raised, and then they are disappointed when the reduction in the number of HAIs does not yield the anticipated cost saving. For this article, we critically review the field and discuss 3 questions. Why measure the cost of an HAI? What outcome should be used to measure the cost of an HAI? What is the best method for making this measurement? The aim is to encourage researchers to collect and then disseminate information that accurately guides decisions about the economic value of expanding or changing current infection control activities.

Entities:  

Mesh:

Year:  2010        PMID: 20178419     DOI: 10.1086/651110

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  42 in total

1.  Economic value of dispensing home-based preoperative chlorhexidine bathing cloths to prevent surgical site infection.

Authors:  Rachel R Bailey; Dianna R Stuckey; Bryan A Norman; Andrew P Duggan; Kristina M Bacon; Diana L Connor; Ingi Lee; Robert R Muder; Bruce Y Lee
Journal:  Infect Control Hosp Epidemiol       Date:  2011-05       Impact factor: 3.254

2.  Economic Analysis of Veterans Affairs Initiative to Prevent Methicillin-Resistant Staphylococcus aureus Infections.

Authors:  Richard E Nelson; Vanessa W Stevens; Karim Khader; Makoto Jones; Matthew H Samore; Martin E Evans; R Douglas Scott; Rachel B Slayton; Marin L Schweizer; Eli L Perencevich; Michael A Rubin
Journal:  Am J Prev Med       Date:  2016-05       Impact factor: 5.043

3.  Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach.

Authors:  Michelle R Ananda-Rajah; Allen Cheng; C Orla Morrissey; Tim Spelman; Michael Dooley; A Munro Neville; Monica Slavin
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

4.  Attributable Cost and Length of Stay Associated with Nosocomial Gram-Negative Bacterial Cultures.

Authors:  Richard E Nelson; Vanessa W Stevens; Makoto Jones; Karim Khader; Marin L Schweizer; Eli N Perencevich; Michael A Rubin; Matthew H Samore
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

5.  Estimating Local Costs Associated With Clostridium difficile Infection Using Machine Learning and Electronic Medical Records.

Authors:  Theodore R Pak; Kieran I Chacko; Timothy O'Donnell; Shirish S Huprikar; Harm van Bakel; Andrew Kasarskis; Erick R Scott
Journal:  Infect Control Hosp Epidemiol       Date:  2017-11-06       Impact factor: 3.254

6.  Prolongation of length of stay and Clostridium difficile infection: a review of the methods used to examine length of stay due to healthcare associated infections.

Authors:  Brett G Mitchell; Anne Gardner
Journal:  Antimicrob Resist Infect Control       Date:  2012-04-20       Impact factor: 4.887

7.  Cost and effects of different admission screening strategies to control the spread of methicillin-resistant Staphylococcus aureus.

Authors:  Tanya Gurieva; Martin C J Bootsma; Marc J M Bonten
Journal:  PLoS Comput Biol       Date:  2013-02-21       Impact factor: 4.475

8.  The increased risks of death and extra lengths of hospital and ICU stay from hospital-acquired bloodstream infections: a case-control study.

Authors:  Adrian G Barnett; Katie Page; Megan Campbell; Elizabeth Martin; Rebecca Rashleigh-Rolls; Kate Halton; David L Paterson; Lisa Hall; Nerina Jimmieson; Katherine White; Nicholas Graves
Journal:  BMJ Open       Date:  2013-10-31       Impact factor: 2.692

9.  Cost-effectiveness of a quality improvement programme to reduce central line-associated bloodstream infections in intensive care units in the USA.

Authors:  Kurt R Herzer; Louis Niessen; Dagna O Constenla; William J Ward; Peter J Pronovost
Journal:  BMJ Open       Date:  2014-09-25       Impact factor: 2.692

10.  The economic burden of patient safety targets in acute care: a systematic review.

Authors:  Nicole Mittmann; Marika Koo; Nick Daneman; Andrew McDonald; Michael Baker; Anne Matlow; Murray Krahn; Kaveh G Shojania; Edward Etchells
Journal:  Drug Healthc Patient Saf       Date:  2012-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.